CVRx, Inc. (CVRX): Price and Financial Metrics Recent IPO


CVRx, Inc. (CVRX): $15.77

1.12 (+7.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CVRX Stock Price Chart Interactive Chart >

Price chart for CVRX

CVRX Price/Volume Stats

Current price $15.77 52-week high $29.00
Prev. close $14.65 52-week low $14.00
Day low $14.80 Volume 310,100
Day high $15.84 Avg. volume 166,493
50-day MA $19.31 Dividend yield N/A
200-day MA $0.00 Market Cap 320.86M

CVRx, Inc. (CVRX) Company Bio


CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.


CVRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CVRX Latest Social Stream


Loading social stream, please wait...

View Full CVRX Social Stream

Latest CVRX News From Around the Web

Below are the latest news stories about CVRx Inc that investors may wish to consider to help them evaluate CVRX as an investment opportunity.

CVRx Added to Russell 2000® and 3000® Indexes

MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced it will be added as a member of the Russell 2000® and 3000® Indexes, effective after the U.S. market opens on September 20, as part of the Russell’s quarterly additions of select initial public offe

Yahoo | September 17, 2021

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACH...

Benzinga | September 16, 2021

CVRx Reports Second Quarter 2021 Financial and Operating Results

Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year

Intrado Digital Media | August 4, 2021

CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Canaccord Genuity 41 st Annual Growth Conference on Thursday, August 12, 2021. The Company is scheduled to present at the conference at 11:00 am Eastern Time the same day via webcast.

Intrado Digital Media | July 29, 2021

Landmark Infrastructure, CVRx See Activist Action

Verde Investments made a bid to acquire land-management REIT Landmark Infrastructure. New Enterprise Associates disclosed a large stake in medical-device maker CVRx.

Yahoo | July 23, 2021

Read More 'CVRX' Stories Here

CVRX Price Returns

1-mo -18.25%
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7454 seconds.